Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 160

1.

The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis.

Kragstrup TW, Andersen T, Heftdal LD, Hvid M, Gerwien J, Sivakumar P, Taylor PC, Senolt L, Deleuran B.

Front Immunol. 2018 Sep 25;9:2226. doi: 10.3389/fimmu.2018.02226. eCollection 2018. Review.

2.

Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA.

Frasca L, Palazzo R, Chimenti MS, Alivernini S, Tolusso B, Bui L, Botti E, Giunta A, Bianchi L, Petricca L, Auteri SE, Spadaro F, Fonti GL, Falchi M, Evangelista A, Marinari B, Pietraforte I, Spinelli FR, Colasanti T, Alessandri C, Conti F, Gremese E, Costanzo A, Valesini G, Perricone R, Lande R.

Front Immunol. 2018 Sep 12;9:1936. doi: 10.3389/fimmu.2018.01936. eCollection 2018.

3.

Evaluation of circulating invariant T cells before and after IL-17 inhibitor treatment in a patient with psoriatic arthritis.

Koga T, Matoba M, Sato T, Koike Y, Endo Y, Sumiyoshi R, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kawakami A.

Clin Immunol. 2018 Sep 21;197:107-109. doi: 10.1016/j.clim.2018.09.011. [Epub ahead of print] No abstract available.

PMID:
30248399
4.

Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis.

Bartosińska J, Zakrzewska E, Purkot J, Michalak-Stoma A, Kowal M, Krasowska D, Chodorowska G, Giannopoulos K.

Postepy Dermatol Alergol. 2018 Aug;35(4):344-350. doi: 10.5114/ada.2018.75609. Epub 2018 Aug 21.

5.

Interleukin-17-producing γδ T (γδ17) cells in inflammatory diseases.

Akitsu A, Iwakura Y.

Immunology. 2018 Aug 22. doi: 10.1111/imm.12993. [Epub ahead of print] Review.

PMID:
30133701
6.

T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities.

Casciano F, Pigatto PD, Secchiero P, Gambari R, Reali E.

Front Immunol. 2018 Jun 19;9:1390. doi: 10.3389/fimmu.2018.01390. eCollection 2018. Review.

7.

Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.

Thibodaux RJ, Triche MW, Espinoza LR.

Expert Opin Biol Ther. 2018 Jul;18(7):821-827. doi: 10.1080/14712598.2018.1492545. Epub 2018 Jul 9.

PMID:
29949399
8.

IL-35: a new immunomodulator in autoimmune rheumatic diseases.

Sakkas LI, Mavropoulos A, Perricone C, Bogdanos DP.

Immunol Res. 2018 Jun;66(3):305-312. doi: 10.1007/s12026-018-8998-3. Review.

PMID:
29749583
9.

Distinct In Vitro T-Helper 17 Differentiation Capacity of Peripheral Naive T Cells in Rheumatoid and Psoriatic Arthritis.

Baricza E, Marton N, Királyhidi P, Kovács OT, Kovácsné Székely I, Lajkó E, Kőhidai L, Rojkovich B, Érsek B, Buzás EI, Nagy G.

Front Immunol. 2018 Apr 4;9:606. doi: 10.3389/fimmu.2018.00606. eCollection 2018.

10.

Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis.

Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y, Yoshikawa M, Yoshinari H, Tanaka Y.

Rheumatology (Oxford). 2018 Apr 2. doi: 10.1093/rheumatology/key069. [Epub ahead of print]

PMID:
29618121
11.

[Biological treatment of psoriatic arthritis].

Štolfa J.

Vnitr Lek. 2018 Spring;64(2):127-135. Czech.

PMID:
29595278
12.

Psoriatic arthritis: tissue-directed inflammation?

Cafaro G, McInnes IB.

Clin Rheumatol. 2018 Apr;37(4):859-868. doi: 10.1007/s10067-018-4012-7. Epub 2018 Feb 23. Review.

PMID:
29476352
13.

Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis.

Yang L, Fanok MH, Mediero-Munoz A, Fogli LK, Corciulo C, Abdollahi S, Cronstein BN, Scher JU, Koralov SB.

Arthritis Rheumatol. 2018 Jun;70(6):855-867. doi: 10.1002/art.40447. Epub 2018 Apr 18.

PMID:
29439292
14.

Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints.

Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C.

Int J Mol Sci. 2018 Feb 9;19(2). pii: E530. doi: 10.3390/ijms19020530. Review.

15.

The enigmatic role of IL-38 in inflammatory diseases.

Garraud T, Harel M, Boutet MA, Le Goff B, Blanchard F.

Cytokine Growth Factor Rev. 2018 Feb;39:26-35. doi: 10.1016/j.cytogfr.2018.01.001. Epub 2018 Jan 12.

PMID:
29366546
16.

Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.

Naik GS, Ming WK, Magodoro IM, Akinwunmi B, Dar S, Poulsen HE, Kristensen LE, Ellervik C.

Dermatology. 2017;233(5):366-377. doi: 10.1159/000484520. Epub 2017 Dec 20.

17.

CXCL4 is a novel inducer of human Th17 cells and correlates with IL-17 and IL-22 in psoriatic arthritis.

Affandi AJ, Silva-Cardoso SC, Garcia S, Leijten EFA, van Kempen TS, Marut W, van Roon JAG, Radstake TRDJ.

Eur J Immunol. 2018 Mar;48(3):522-531. doi: 10.1002/eji.201747195. Epub 2018 Jan 15.

18.

Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.

Toussirot E.

Expert Opin Biol Ther. 2018 Jan;18(1):101-107. doi: 10.1080/14712598.2018.1410133. Epub 2017 Nov 29. Review.

PMID:
29187009
19.

Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab.

Jauregui-Amezaga A, Somers M, De Schepper H, Macken E.

Clin Exp Gastroenterol. 2017 Nov 15;10:293-301. doi: 10.2147/CEG.S110546. eCollection 2017. Review.

20.

The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling.

Razawy W, van Driel M, Lubberts E.

Eur J Immunol. 2018 Feb;48(2):220-229. doi: 10.1002/eji.201646787. Epub 2018 Jan 15. Review.

Supplemental Content

Loading ...
Support Center